JeffreyJCrowleyMD
Dermatology • Bakersfield, CADermatologic Surgery
Bakersfield Dermatology and Skin Cancer Medical Group
Dr. Crowley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5101 Commerce Dr
Ste 101
Bakersfield, CA 93309Phone+1 661-327-3756Fax+1 661-327-2332
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 1992 - 1995
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1993 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FAAD) American Academy of Dermatology
- Fellow (FASDS) American Society for Dermatologic Surgery
Clinical Trials
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis Start of enrollment: 2019 Oct 29
- Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Start of enrollment: 2020 Feb 03
- Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Start of enrollment: 2020 Jun 15
Publications & Presentations
PubMed
- Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestation...Bruce Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda Gooderham
Journal of the European Academy of Dermatology and Venereology. 2024-05-01 - 1 citationsSpeed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) vers...Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H Chih-Ho Hong, Meghan Feely
Dermatology and Therapy. 2024-02-01 - 5 citationsSafety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.Andrew Blauvelt, Diamant Thaçi, Kim A Papp, Vincent Ho, Kamran Ghoreschi
The British Journal of Dermatology. 2023-07-07
Authored Content
- A Brief Guide to Pustular Psoriasis for Primary Care ProvidersSeptember 2020
Press Mentions
Experts See Strides on AIDS, but COVID-19 Halted Progress – CBS Sacramento – Sacramento, CaliforniaJune 4th, 2021
Trump Virus Adviser Is a Rarity in White House Ruled by LoyaltyMarch 10th, 2020
Long-Term Benefit in Psoriasis with Monoclonal AntibodyOctober 15th, 2019- Join now to see all
Professional Memberships
- Fellow
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
